The traditional view of how intracellular effector proteins are recruited to the B cell antigen receptor (BCR) complex at the plasma membrane is based on the occurrence of direct protein-protein interactions, as exemplified by the recruitment of the tyrosine kinase Syk (spleen tyrosine kinase) to phosphorylated motifs in BCR signaling subunits. By contrast, the subcellular targeting of the cytosolic adaptor protein SLP-65 (Src homology 2 domain-containing leukocyte adaptor protein of 65 kD), which serves as a proximal Syk substrate, is unclear. We showed that SLP-65 activation required its association at vesicular compartments in resting B cells. A module of ∼50 amino acid residues located at the amino terminus of SLP-65 anchored SLP-65 to the vesicles. Nuclear magnetic resonance spectroscopy showed that the SLP-65 amino terminus was structurally disordered in solution, but could bind in a structured manner to noncharged lipid components of cellular membranes. Our finding that preformed vesicular signaling scaffolds are required for B cell activation indicates that vesicles may deliver preassembled signaling cargo to sites of BCR activation.
INTRODUCTION
Various modes of direct protein-protein interactions play central roles in coupling the ligated B cell antigen receptor (BCR) to its downstream signal effectors. Most notable are the inducible and constitutive associations mediated by Src homology (SH) 2 and 3 domains, respectively (1) . The tandem SH2 domains of the tyrosine kinase Syk (spleen tyrosine kinase) bind to doubly phosphorylated versions of the immunoreceptor tyrosinebased activation motifs (ITAMs) in the BCR signaling subunits immunoglobulin a (Ig-a) (CD79a) and Ig-b (CD79b) (2) . This arrangement equips the activated BCR with enzymatic activity. Similarly, the SH2 domaincontaining leukocyte adaptor protein of 65 kD (SLP-65) (3), which is also called BLNK (4) , has a distinct phosphotyrosine-based docking site in Ig-a (5, 6) . The binding of SLP-65 to Ig-a facilitates Syk-mediated phosphorylation of SLP-65, which is instrumental for the activation of a plethora of B cell signaling cascades and, hence, humoral immunity in mouse and humans (7, 8) . Moreover, the SH2 domain of SLP-65 can bind to phosphorylated Syk directly (9) .
In addition to these inducible protein-protein interactions, SLP-65 also requires a constitutive association with Cbl-interacting protein of 85 kD (CIN85) to translocate to the plasma membrane, and for the concomitant triggering of B cell activation pathways (10) . Permanent complex formation between SLP-65 and CIN85 involves three proline-rich motifs in the central part of SLP-65 and the three N-terminal SH3 domains of CIN85. Exactly how CIN85 controls the subcellular movement of SLP-65 is unclear; however, the SLP-65 recruitment process appears to be even more complex. Mutational analyses showed that a short N-terminal SLP-65 segment of about 50 amino acid residues is indispensable for SLP-65 signaling (11) . Furthermore, deletion of the N terminus of SLP-65 interfered neither with the functionality of the SLP-65 SH2 domain nor with the ability of SLP-65 to form a complex with CIN85 (12, 13) . These findings demonstrated that, in addition to the SH2 domain and the CIN85-binding sites, the N-terminal region of SLP-65 constitutes a third and separate targeting device that controls a nonredundant route of SLP-65 activation.
The mode of action of the N terminus of SLP-65 remains unclear. It is characterized by a large number of basic and aliphatic amino acid residues. A putative leucine zipper motif was predicted to recognize a ligand leucine zipper in membrane-targeting proteins (11) . The elucidation of the SLP-65 interactome by SILAC (stable isotope labeling by amino acids in cell culture)-based quantitative mass spectrometry did not, however, reveal a protein ligand for a putative leucine zipper or any other part of the N terminus of SLP-65 (13) . Here, we showed that the N terminus of SLP-65 mediated direct protein-lipid interactions. Unexpectedly, the lipid-binding activity of SLP-65 was required for B cell activation before BCR stimulation occurred to position SLP-65 in cooperation with CIN85 at small, exosome-like intracellular compartments. Our data suggest that the ability of SLP-65 to respond to BCR activation requires its stimulationindependent residence at vesicular compartments that may en masse deliver a preformed cargo of signaling effector molecules to sites of BCR activation. This process would provide an efficient mechanism to amplify signal initiation and processing at activated receptors.
RESULTS
Signaling-competent SLP-65 resides in particulate cell compartments Köhler et al. and our own group previously showed that the N terminus of SLP-65 is essential to receive and process signals from the activated BCR ( fig. S1) (11, 12) . To investigate the underlying mechanism, we visualized the subcellular distribution of citrine-tagged versions of wild-type and N-terminally truncated SLP-65 (DN-SLP-65) with laser scanning confocal microscopic analysis of resting and BCR-activated transductants of the chicken B cell line DT40 (Fig. 1A) . In the absence of BCR stimulation, wild-type SLP-65 was localized in intracellular speckles that were distributed throughout the cytoplasm (Fig. 1A) . These dot-like structures entirely disappeared 1 min after BCR engagement (Fig. 1A) . Instead, SLP-65-derived fluorescent signals were detected at the plasma membrane, reflecting the BCR-induced translocation of SLP-65. Unlike wild-type SLP-65, the DN-SLP-65 variant was almost uniformly dispersed in the cytoplasm of both unstimulated and stimulated B cells ( Fig. 1A) . These data confirmed the importance of the N terminus for the relocalization of SLP-65 upon BCR activation, and moreover revealed that the N terminus controls SLP-65 localization even in resting B cells.
The dot-like appearance of SLP-65 could be explained by multimerization of wild-type SLP-65 or by its residence in defined subcellular compartments. We could not coimmunoprecipitate differently tagged versions of SLP-65 from transduced B cells, which suggested that direct oligomerization of SLP-65 was unlikely ( fig. S2) . We thus established a Balch homogenizer-based cell fractionation assay that enabled us to disrupt B cells in the absence of detergent and, hence, to preserve membranous cell compartments that could be further separated from the soluble molecules of the cytosol by ultracentrifugation on a sucrose gradient. In this setting, particulate cell fractions floated to the interphases of the sucrose gradient, whereas soluble molecules of the cytosol remained at the bottom of the centrifugation tube. Subsequently, individual cell fractions were subjected to Western blotting analysis with antibodies specific for SLP-65 or the serine and threonine kinase Akt, which served as a marker for cytosolic proteins (Fig. 1B) . In contrast to Akt, signaling-competent wild-type SLP-65 of chicken and human B cells was found in the cytosolic fraction and in interphase 2 ( Fig. 1B and fig. S3 ). Interphase 2 accommodated cell compartments that were of a higher density than those that migrated in interphase 1, which contained only minute amounts of wild-type SLP-65 (Fig. 1B) . By contrast, DN-SLP-65 was exclusively found in the cytosolic fraction (Fig. 1B) . Likewise, a signaling-incompetent point mutant of SLP-65 containing a leucine-to-lysine substitution at position 18 (L18K) was purely cytosolic (Fig. 1B) . These data show that the presence of a functional N terminus is associated with the ability of SLP-65 to reside in particulate cell fractions. Note that not only deletion of the entire N terminus of SLP-65 but also substitution of a single amino acid residue that preserves the overall positive charge of the N terminus blocked all three aspects of SLP-65 function: signal-independent localization to noncytosolic compartments, inducible translocation to the plasma membrane, and signaling ( fig. S4 ).
The N-terminal segment of SLP-65 constitutes a membrane-binding module Next, we performed an in vitro floatation assay to investigate whether the N terminus targeted SLP-65 to membrane compartments directly or whether this occurred indirectly because of an association between the SLP-65 N terminus and a protein ligand that itself was attached to or integrated into cellular membranes. We therefore prepared small unilamellar vesicles (SUVs) composed of 75% phosphatidylcholine and 25% phosphatidylethanolamine and incubated them with recombinant wild-type SLP-65 protein or its N-terminal mutants, DN-SLP-65 and L18K-SLP-65. After ultracentrifugation on a Nycodenz gradient, SUVs and potentially bound proteins floated to the top of the tube, whereas soluble proteins became gradually distributed in the tube. Individual fractions were analyzed by Western blotting with an anti-SLP-65 antibody as described earlier (Fig. 1C) . Wild-type SLP-65 was concentrated in the SUV fractions and was almost absent in the soluble fractions. Conversely, none of the two signaling-incompetent SLP-65 mutants floated with the SUVs, but remained soluble (Fig. 1C) . Hence, these data suggest that the N terminus of SLP-65 is capable of directly binding to general components of cellular membranes.
This result was further corroborated by nuclear magnetic resonance (NMR) spectroscopy, which demonstrated that the isolated SLP-65 N terminus was intrinsically disordered in solution ( Fig. 1D and fig. S5 ) as inferred from calculations based on the chemical shifts of backbone amides, Ca and Cb resonances (14) . NMR spectroscopy also confirmed that the N terminus associated directly with liposomes ( Fig. 1E and fig.  S5 ). The formation of a helical structure upon liposome binding is likely given that hydrophobic residues appear every 3.5 residues in the membranebinding N-terminal segment. Moreover, this analysis identified individual amino acid residues that were in direct contact with the membrane (Fig. 1E ). These were mainly hydrophobic and basic residues and included Leu 18 , which was identified by our mutational analysis to be indispensable for SLP-65 signaling. In addition, those aliphatic residues of the predicted leucine zipper (11) were tightly involved in SUV binding. However, inactivation of the motif by exchange of the central Ile 25 for other aliphatic residues, such as alanine, which preserves interactions with hydrophobic membranes, or lysine, which maintains the basic nature of the N terminus, only marginally impaired SLP-65-induced Ca 2+ signaling ( fig. S6 ). Our data excluded the possibility of a functional leucine zipper motif and suggest that the N terminus confers signaling competence to SLP-65 by tethering this BCR effector directly to intracellular membranes. Hence, the N terminus-dependent dot-like structures of SLP-65 observed in B cells (Fig. 1A) appear to represent macromolecular assemblies of signaling-competent SLP-65 at intracellular vesicular compartments.
SLP-65-positive vesicles accommodate exosomal marker proteins
To further characterize vesicular SLP-65 in the cell, we used confocal microscopy to monitor the potential colocalization of citrine-tagged wildtype SLP-65 with various cerulean-tagged vesicular marker proteins that are characteristic for compartments of the trans-Golgi network or the endocytic and exocytic pathways in resting DT40 cells ( Fig. 2A) . No colocalization of SLP-65 was observed with the trans-Golgi network marker TGN38 or with a cerulean-labeled fusion protein that encompasses the pleckstrin homology (PH) domain of oxysterole-binding protein 1 (OSBP1). The OSBP1-PH domain binds with distinct specificity to phosphatidylinositol-4-monophosphate (PIP4), which resides exclusively in Golgi-proximal vesicles (15) . Similarly, labeling of vesicles with cerulean-tagged Rab proteins that are specific for endosomes, with the soluble N-ethylmaleimidesensitive protein attachment protein receptor (SNARE) family member SNAP23, or with syntaxin 8 did not reveal colocalization with SLP-65 ( Fig. 2A and fig. S7 ). SLP-65 was also absent from Rab8-and Rab27-positive exosomal compartments ( Fig. 2A) .
We observed marked colocalization of SLP-65 with VAMP7 (vesicleassociated membrane protein 7), a member of the family of SNARE molecules that is mainly located at exosomes (16) , and with quinacrine, which stains ATP (adenosine 5′-triphosphate)-containing exosomes ( Fig. 2A ) (17) . Quantification of the colocalization confirmed the specific residence of wild-type SLP-65 at this distinct species of exosome-like vesicles in resting B cells (Fig. 2B) . Further evidence for the N terminus-dependent attachment of SLP-65 to VAMP7-positive vesicles was obtained by a bimolecular fluorescence complementation assay in which the two proteins were fused to either the N-or the C-terminal parts of the Venus fluorophore, respectively. In transduced B cells that contained both fusion proteins, the two portions of Venus could combine to complement the fluorescence signal ( fig. S8) . No signal was observed in cells containing Venus-tagged DN-SLP-65 ( fig. S8) . However, the vesicular colocalization of SLP-65 and VAMP7 does not necessarily imply that the two proteins are structurally linked or that VAMP7 directly contributes to SLP-65 signaling. Indeed, fluorescence recovery after photobleaching (FRAP) analysis revealed that the vesicular pool of SLP-65, but not VAMP7, rapidly exchanged with the cytosolic pool ( fig. S9 ). The latter result also excluded the possibility that SLP-65 was located inside the vesicles. Together, our findings suggest that the ability of SLP-65 to receive and process upstream activation signals depends on its ability to assemble at vesicular platforms before BCR stimulation occurs. The exact composition and nature of the SLP-65-positive vesicles remain to be determined; however, they may function as a shuttle that delivers a preformed signaling cargo to sites of BCR activation at the plasma membrane.
Anchoring SLP-65 to trans-Golgi vesicles initiates vesicular routing
The microscopic characterization of the vesicular pool of SLP-65 together with the results of our floatation assays and NMR analysis suggested that the N terminus of SLP-65 directly targets the protein to exosome-like signaling organelles. Indeed, the DN-SLP-65 mutant showed no colocalization with VAMP7-positive exosomes (Fig. 3, A and B) . However, we previously described that the SLP-65 binding partner CIN85 contributes to both the precise subcellular localization and the signaling function of the stable SLP-65-CIN85 complex (13) . To assess the effect of CIN85 on the vesicular residence of SLP-65, we inactivated the proline-rich docking sites for CIN85 in SLP-65 and expressed the resulting SLP-65 mutant (DPRR-SLP-65) as a citrine fusion protein in slp-65 -/-DT40 cells. We found that the loss of CIN85 binding, which is associated with SLP-65 signaling deficiency (13) , resulted in SLP-65 becoming trapped in the trans-Golgi network compartment, as evidenced by its colocalization with the fluorescent fusion protein containing the PH domain of OSBP1 (Fig.  3, C and D) . This result suggests that there is cooperation between the N terminus of SLP-65 and CIN85 to tether SLP-65 to vesicular membranes with exosomal markers in resting B cells. It moreover suggested that the N terminus of SLP-65 provides a membrane anchor for Golgi-proximal vesicles. To directly test this hypothesis with a functional readout, we replaced the N terminus of wild-type SLP-65 or the DPRR-SLP-65 variant with the PH domain of the specific PIP4-binding protein OSBP1 (Fig. 4A) , which associates with exquisite specificity to trans-Golgi membranes. Expression of the PH domain chimera of SLP-65 in slp-65 −/− DT40 cells recapitulated the subcellular distribution of the OSBP1-PH domain (Fig. 4B) . Although the OSBP1-PH domain did not target SLP-65 to VAMP7-positive exosomes ( fig. S10) , it reconstituted the BCR-triggered phosphorylation of SLP-65 and Ca 2+ mobilization (Fig. 4, C and D) . Thus, the N terminus of SLP-65 could be functionally replaced by a trans-Golgi-specific anchor under conditions of CIN85 binding. By contrast, the PH domain chimera of DPRR-SLP-65 mutant, which lacks CIN85-binding sites, only moderately supported BCR-dependent SLP-65 phosphorylation and Ca 2+ mobilization (Fig. 4, C and D) . On the basis of these findings, we suggest that precise vesicular tethering is primed by the N terminus of SLP-65 and then complemented by the constitutive SLP-65 binding partner CIN85.
DISCUSSION
The processing of signals emanating from the activated BCR relies on phosphorylation of the adaptor protein SLP-65 by the tyrosine kinase Syk. It is well established that this process is indispensable for B cell activation and humoral immunity; however, the details of how and where Syk encounters its substrate SLP-65 were unclear. Here, we showed that in addition to undergoing classical protein-protein interactions, SLP-65 requires tethering at exosome-like vesicles for its phosphorylation and signaling. Our biochemical approaches and NMR spectroscopy showed that the 50 N-terminal amino acid residues of SLP-65 acted as a direct membrane-anchoring device, which represents a previously uncharacterized type of lipid-binding domain. Furthermore, the N terminus of SLP-65 could be experimentally substituted by the OSBP1-PH domain, which does not bind to plasma membrane components, but constitutively recognizes PIP4 in postGolgi vesicles with exquisite specificity (15) . First, this result excludes the possibility that the lipid-binding activity of the N terminus recruits cytoplasmic SLP-65 to the inner leaflet of the plasma membrane in response to BCR stimulation. Instead, the N terminus mediates the assembly of SLP-65 complexes at vesicles already before the BCR is stimulated. Second, this result suggests that the N terminus alone is not sufficient to localize SLP-65 at exosome-like vesicles that contain VAMP7 and are detectable by quinacrine. Further evidence that additional elements are required for the vesicular localization of SLP-65 is provided by the ability of the N terminus of SLP-65 to bind to more general components of cellular membranes. Indeed, colocalization of SLP-65 with exosomal markers required stable association with its binding partner CIN85. These data suggest that the N terminus of SLP-65 and CIN85 cooperate, most likely in a sequential manner, for the subcellular targeting of the SLP-65-CIN85 signaling complex. The exact contribution of CIN85 remains to be elucidated; however, our data suggest that the presence of SLP-65 at vesicular compartments is a precondition for the sensing of BCR-derived signals and for subsequent B cell activation.
What is the biological advantage of the stimulation-independent, vesicular preassembly of SLP-65-CIN85 complexes for BCR signaling? A critical and common feature of signal transduction by cell surface receptors is the aspect of signal amplification. Syk easily accomplishes this task because its enzymatic activity suffices to phosphorylate a large quantity of downstream substrates despite its direct recruitment to the BCR with limited stoichiometry. By contrast, SLP-65 and CIN85 are inert adaptor proteins that cannot amplify the engagement of BCR signal effectors unless they oligomerize. Vesicular scaffolding of SLP-65, CIN85, and perhaps additional effectors provides a potent way to facilitate signal transmission by rapid, en masse delivery of a large, and perhaps complex, signaling cargo to the activated BCR. The necessary transport machinery might involve SNARE family proteins, such as VAMP7, which participates in intracellular trafficking and secretory pathways in several cell types (16) , and which plays a role in the vesicular delivery of effector proteins to the T cell receptor complex (18, 19) .
BCR-induced reorganization of the actin cytoskeleton (20) may actively or passively contribute to the process of SLP-65 recruitment by providing defined vesicle transport fibers or by releasing a cytoskeletal fence that in resting B cells prevents signaling vesicles from entering a cortical exclusion zone, respectively. In support of the later possibility, pharmacological disruption of the cytoskeletal network in B cells mimics BCR activation (20) . In any case, our data argue against the common view that the initiation and processing of BCR signals rely solely on the sequential relocalization of individual signaling effectors to and at the plasma membrane. Instead, it appears that multimolecular effector complexes are preassembled at distinct signaling organelles already in the resting B cell, for which genetic evidence already existed (21) .
An association with intracellular vesicles was reported for the z subunit of the T cell antigen receptor (TCRz), as well as for the kinase Lck and the adaptor protein linker of activated T cells (LAT), which are effectors downstream of the TCR (18, 19) . In contrast to SLP-65, however, the membrane anchors of all three of these T cell signaling proteins are well characterized. Similar to other Src family kinase members, the protein tyrosine kinase Lck is attached to cellular membranes by its N-terminal myristoyl anchor, whereas TCRz and LAT both have classical transmembrane regions. In spite of their more general mode of membrane anchoring, but similar to SLP-65, these T cell signaling elements are targeted to transport vesicles that contain exosomal markers, including VAMP7 (18, 19) . The T cell paralog of SLP-65, SLP-76, is not directly associated with VAMP7-positive vesicles, which suggests that the intracellular localization of SLP-76 is mainly regulated by its binding partners, for example, LAT (18, 19) . However, vesicular LAT may represent only a proportion of the total LAT involved in signaling (22) , and the timing of the delivery of vesicular TCR effectors to the plasma membrane may lag behind that required for early TCR signaling (23) . Nonetheless, the vesicular localization of T cell effectors was associated with productive TCR activation and the formation of a functional immunological synapse upon TCR ligation. Thus, a concept emerges, according to which the signaling competence of lymphocyte antigen receptors may be associated with the vesicular targeting and transport of their intracellular effector proteins. It will be interesting to investigate this concept in other receptor systems and to elucidate the inventory of SLP-65-positive signaling organelles.
MATERIALS AND METHODS
Cell culture, microscopy, and signaling analyses DT40 cells were cultured, stimulated, and biochemically analyzed as described previously (24) . Antibodies against GFP (Roche), phosphotyrosine (4G10, Millipore), SLP-65 (clone 2B11, BD Biosciences), and Akt (Cell Signaling Technology) were used for Western blotting analysis (at a 1:1000 dilution) and for immunoprecipitations (0.2 to 1 mg per reaction). Ratiometric Ca 2+ flux measurements were recorded by flow cytometry, as described previously (24) . For live-cell confocal laser scanning microscopy (24), contrast, background subtraction, Gauss filtering, and colocalization analysis were applied with ImageJ software.
Expression constructs, transfections, and retroviral gene transfer
The complementary DNAs (cDNAs) encoding vesicular markers were amplified by reverse transcription polymerase chain reaction (RT-PCR) and subcloned into the expression plasmid pEGFP-N1 (BD Biosciences), in which the sequence encoding EGFP (enhanced green fluorescent protein) was replaced by that encoding cerulean, and subsequently cloned into pMSCV (BD Biosciences) containing a puromycin or bleomycin resistance cassette. The SLP-65-encoding constructs used were described previously (13) . Point mutations were generated by site-directed mutagenesis with the QuikChange protocol (Stratagene). Constructs encoding chimeric proteins containing the OSBP1-PH domain (amino acid residues 87 to 189) and a SLP-65 variant lacking the 45 N-terminal amino acids were generated by overlap extension PCR. DT40 B cells were transduced with retroviruses encoding SLP-65 proteins or vesicular marker proteins, as described previously (24) , and transduced cells were selected with puromycin (1 mg/ml; InvivoGen) or bleomycin (70 mg/ml; Merck).
Liposome floatation assays
For an in vitro analysis of the ability of SLP-65 to bind to SUVs by liposome floatation, recombinant SLP-65 protein was generated. Escherichia coli (BL21) cells transformed with pET16b plasmid encoding SLP-65 were grown in 100 ml of Luria broth medium containing ampicillin until they reached an OD 600 (optical density at 600 nm) of 0.6. The E. coli were then incubated for 4 hours with 0.1 mM IPTG (isopropyl-b-D-thiogalactopyranoside) to induce expression of SLP-65. Bacteria were suspended in LEW buffer [50 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl] and lysed by sonification. His-tagged SLP-65 was purified with Protino Ni-IDA columns (MachereyNagel) according to the manufacturer's instructions. Protein concentrations were measured with the Bradford assay. For liposome floatation, proteins were diluted in LEW buffer to a final concentration of 1 mM. SUV preparation and liposome floatation were performed as described previously (25) , except that LEW buffer was used for SUV preparation and the Nycodenz gradient. SUVs were composed of 75% phosphatidylcholine and 25% phosphatidylethanolamine, of which 2% were labeled with Texas Red as tracer.
Subcellular B cell fractionation
DT40 cells were fractionated as previously described (26) . Briefly, 3 × 10 8 cells were suspended in 250 mM sucrose, 25 mM Hepes, 20 mM KCl, 2.5 mM Mg(OAc) 2 and were disrupted by being passed 30 times through a Balch homogenizer. Upon sedimentation of nuclei, the supernatant was adjusted to a sucrose concentration of 55% and overlaid with 2 ml of 45%, 3 ml of 35%, and 3 ml of 25% sucrose. Upon centrifugation for 5 hours at 217,000g, fractions were collected and analyzed by Western blotting.
NMR spectroscopy
A cDNA fragment encoding amino acid residues 5 to 50 of SLP-65 was amplified by PCR and subcloned into a modified pET28a vector (Novagen). The uniformly 13 C, 15 N-labeled SLP-65 fragment was produced recombinantly in E. coli strain BL21(DE3) in minimal medium supplemented with 13 C-glucose and 15 N-NH 4 Cl and was purified by immobilized metal affinity chromatography on Ni-NTA agarose (Qiagen). After proteolytic cleavage by tobacco etch virus (TEV) protease, the N-terminal His tag was removed by incubation with Ni-NTA agarose. After further purification by reversed-phase high-performance liquid chromatography, the SLP-65 fragment was dialyzed against NMR buffer [20 mM Hepes (pH 6.9), 150 mM KCl]. Final protein concentrations were adjusted to 3.2 mM in the sample for triple resonance experiments and to 0.1 mM to test interactions with liposomes. The samples were subjected to HNCACB (27) and CBCAcoNH (28) C) in the first frequency dimension with the directly bound proton in the second frequency dimension. TOCSY (total correlation spectroscopy) correlates all nuclei of the same isotope that are present within a coupling network, whereas NOESY (nuclear Overhauser effect spectroscopy) correlates two protons that are close in space in two frequency dimensions. The randomcoil index was obtained as part of a TALOS-N calculation (32) . The wateramide proton exchange rate was determined by CLEANEX-PM (33) , with different mixing times of 5, 10, 25, and 50 ms. Liposomes composed of 75% phosphatidylcholine and 25% phosphatidylethanolamine (mol/mol) were prepared by extensive sonication in NMR buffer at a total initial lipid concentration of 12.5 mM. From this solution, large multilamellar vesicles were removed by ultracentrifugation for 2 hours at 163,000g at 25°C. The supernatant, which consisted mostly of unilamellar vesicles, was subsequently used for NMR titrations.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/7/339/ra79/DC1 Fig. S1 . The N terminus of SLP-65 is essential for the BCR-dependent activation of ERK. 
